Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Eyenovia, Inc.
  6. Summary
    EYEN   US30234E1047

EYENOVIA, INC.

(EYEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/14/2021 09/15/2021 09/16/2021 09/17/2021 09/20/2021 Date
4.43(c) 4.46(c) 4.46(c) 4.5(c) 4.45 Last
176 427 115 176 70 516 155 498 133 347 Volume
+0.91% +0.68% 0.00% +0.90% -1.11% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 5,24 M - -
Net income 2021 -23,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,43x
Yield 2021 -
Sales 2022 9,77 M - -
Net income 2022 -22,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -6,54x
Yield 2022 -
Capitalization 115 M 115 M -
Capi. / Sales 2021 22,1x
Capi. / Sales 2022 11,8x
Nbr of Employees 33
Free-Float 63,8%
More Financials
Company
Eyenovia, Inc. is a clinical stage ophthalmic company. The company is developing a pipeline of therapeutics based microdose array print (MAP) platform technology. Its pipeline is focused on the late-stage development of microdosed medications for progressive myopia, presbyopia, and mydriasis. MydCombi is a combination micro-formulation product (phenylephrine-tropicamide) candidate for pharmacologic mydriasis (eye... 
Sector
Pharmaceuticals
Calendar
11/16Earnings Release
More about the company
Ratings of Eyenovia, Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about EYENOVIA, INC.
09/17EYENOVIA : Arctic Vision Expand Licence Deal to Include Another Eye Drug
MT
09/17Arctic Vision Announces Addition of Novel Mydriatic Drug MydcombiÖ to Eyenovi..
CI
09/15EYENOVIA : Material Definitive Agreement (Form 8-K)
PU
09/15EYENOVIA, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
09/15Eyenovia, Inc. Enters into Amendment to Certain License Agreement with Arctic..
CI
08/12EYENOVIA : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
08/11EYENOVIA : Announced positive topline data from its Phase 3 VISION-1 study evalu..
PU
08/11EYENOVIA, INC. : Results of Operations and Financial Condition, Other Events, Fi..
AQ
08/11Eyenovia, Inc. Reports Earnings Results for the Second Quarter Ended June 30,..
CI
08/11Eyenovia Reports Second Quarter 2021 Financial Results
GL
08/04Eyenovia to Report Second Quarter 2021 Results on Wednesday, August 11
GL
07/19EYENOVIA : to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021
BU
07/07Eyenovia to Participate in Two Upcoming Investor Conferences
GL
06/21EYENOVIA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/16EYENOVIA, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
More news
News in other languages on EYENOVIA, INC.

- No features available -

More news
Analyst Recommendations on EYENOVIA, INC.
More recommendations
Chart EYENOVIA, INC.
Duration : Period :
Eyenovia, Inc. Technical Analysis Chart | EYEN | US30234E1047 | MarketScreener
Technical analysis trends EYENOVIA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 4,45 $
Average target price 15,50 $
Spread / Average Target 248%
EPS Revisions
Managers and Directors
Sean Ianchulev President, CEO, Director & Chief Medical Officer
John P. Gandolfo Chief Financial Officer & Secretary
Fredric N. Eshelman Chairman
Luke Clauson VP-Engineering, Research & Development
Jennifer Clasby VP-Clinical Operations & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
EYENOVIA, INC.-25.74%117
JOHNSON & JOHNSON4.09%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.19.23%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY37.19%208 604